



## **Express Mail No. <u>EV 452 775 546 US</u>**

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Muller et al.

Confirmation No.:

2627

Serial No.:

10/622,618

Art Unit:

1626

Filed:

July 17, 2003

Examiner:

R. Anderson

For:

NOVEL

Attorney Docket No:

9516-200-999

**IMMUNOTHERAPEUTIC** 

(CAM: 501872-999199)

**AGENT** 

## TERMINAL DISCLAIMER UNDER 37 C.F.R. 1.321(c)

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Celgene Corporation is the assignee of the entire right, title and interest in and to U.S. Patent No. 5,929,117 ("the '117 patent") by virtue of an assignment from George W. Muller and Mary Shire to Celgene Corporation recorded in the United States Patent and Trademark Office ("USPTO") on June 14, 1999 at Reel 010017 / Frame 0672.

Celgene Corporation is also the assignee of the entire right, title and interest in and to the above-identified application by virtue of the assignment from George W. Muller and Mary Shire to Celgene Corporation recorded in the USPTO in connection with the '117 patent. The above-identified application is a continuation of U.S. App. No. 10/243,927, filed September 13, 2002, which is a division of U.S. App. No. 09/906,155, filed July 16, 2001 (now U.S. Patent No. 6,479,554), which is a division of U.S. App. No. 09/639,757, filed August 16, 2000 (now U.S. Patent No. 6,262,101), which is a division of the '117 patent.

Celgene Corporation hereby disclaims the terminal part of any patent granted on the above-identified application which would extend beyond the expiration date of the '117 patent, and hereby agrees that any patent so granted on the above-

1

identified application shall be enforceable only for and during such period that the legal title to said patent shall be the same as the legal title to the '117 patent.

Petitioner does not disclaim any terminal part of any patent granted on the above-identified application prior to the expiration of the full statutory term of '117 patent in the event that the '117 patent later: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid, is statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. 1.321(a), has all claims canceled by a reexamination certificate, or is otherwise terminated prior to the expiration of its full statutory term, except for the separation of legal title stated above.

A fee of \$ 110.00 is believed due under 37 C.F.R. 120(d) for the submission of this terminal disclaimer. Please charge this, and any other required fees, to Jones Day Deposit Account No. 503013. A copy of this sheet is enclosed.

Date:

June 27, 2005

Respectfully submitted, Anthony M. Inoogu, Res. No. 35,203 By: Mrif D. Brunn, Res. No. 47,458

Anthony M. Insogna (Reg. No. 35,203)

JONES DAY 222 East 41st Street New York, New York 10017 (858) 314-1130